Entera Bio (NASDAQ:ENTX – Get Free Report) posted its earnings results on Friday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06), Zacks reports.
Entera Bio Stock Performance
Entera Bio stock traded up $0.05 during mid-day trading on Friday, reaching $2.87. 244,911 shares of the company were exchanged, compared to its average volume of 4,887,891. The firm’s 50-day simple moving average is $1.85 and its two-hundred day simple moving average is $1.49. Entera Bio has a twelve month low of $0.91 and a twelve month high of $4.20. The firm has a market cap of $141.46 million, a PE ratio of -10.63 and a beta of 1.38.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on ENTX shares. HC Wainwright reaffirmed a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Entera Bio currently has a consensus rating of “Hold” and a consensus target price of $9.00.
Institutional Investors Weigh In On Entera Bio
Several large investors have recently modified their holdings of the stock. Superstring Capital Management LP purchased a new position in Entera Bio in the 4th quarter valued at $33,000. Renaissance Technologies LLC raised its position in Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares during the last quarter. HighTower Advisors LLC raised its position in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares during the last quarter. Citadel Advisors LLC lifted its stake in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after acquiring an additional 28,322 shares during the period. Finally, Schonfeld Strategic Advisors LLC lifted its stake in shares of Entera Bio by 5.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after acquiring an additional 29,629 shares during the period. Hedge funds and other institutional investors own 14.11% of the company’s stock.
About Entera Bio
Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.
The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.
See Also
- Five stocks we like better than Entera Bio
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
